Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial - Mustafa Özgürŏ glu, Tibor Csőszi, Susanna Y.-S. Cheng, Aude Fléchon, Alejo Rodriguez-Vida, Kentaro Imai, Thomas Powles, Evan Y. Yu, Diana Vera Cascallar, Mirta Varela, Mauricio Fernandez Lazzaro, Diego Lucas Kaen, Gabriela Gatica, Tibor Cs̋ oszi, David Hugo Flores - Dissemin

Language
Login

Published in

Elsevier, The Lancet Oncology, 7(22), p. 931-945, 2021

DOI: 10.1016/s1470-2045(21)00152-2

Links

Tools

Export citation

Search in Google Scholar

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Journal article published in 2021 by Mustafa Özgürŏ glu, Tibor Csőszi, Susanna Y.-S. Cheng, Aude Fléchon, Alejo Rodriguez-Vida, Kentaro Imai, Thomas Powles, Evan Y. Yu, Diana Vera Cascallar, Mirta Varela, Mauricio Fernandez Lazzaro, Diego Lucas Kaen, Gabriela Gatica, Tibor Cs̋ oszi, David Hugo Flores and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO